Navigation Links
Maximizing the Potential of Multi-Drug Portfolios without Undermining a Legacy Brand
Date:5/5/2011

CHAPEL HILL, N.C., May 5, 2011 /PRNewswire/ -- In today's highly competitive marketplace, bio-pharmaceutical companies often look to expand their product portfolios in the same indication. This "double-dipping" can result in a new brand gaining more profitability at the expense of a more established brand. The challenge for all product and brand leaders is to introduce the new product so that it does not affect the sales of the established brand while remaining competitive.

To help companies to meet this critical challenge, Best Practices, LLC has published "Expanding a Product Portfolio without Cannibalizing an Established Brand," a 61-page report that provides superior marketing and branding strategies for expanding a product portfolio without cannibalizing an existing brand.

While it can be a complex decision, having more than one brand in a therapeutic area clearly pays off for an organization - 96 percent of the study participants realized positive benefits of introducing a new brand treating an indication for which it had an existing product. More than 70 percent of the benchmark class identified market leadership, expanded market share and enhancing brand reputation among physicians as major contributing factors for marketing multiple products.

Participants in the study successfully used a range of positioning strategies to prevent or control cannibalization. Fifty percent or more of the benchmark class rated 10 positioning strategies somewhat effective to very effective at minimizing product cannibalization. Targeting different patient subtypes and aligning with thought leaders are among those positioning strategies rated effective by more than 80 percent of the benchmark class.

Topics covered in this study include:

  • Effective methods of differentiating multiple brands
  • Positioning strategies that minimize product cannibalization
  • Operational changes that drive success when introducing a new brand into a product family
  • Positive and negative impacts of introducing a new brand
  • New product's share of the combined marketing spend during first three years both are marketed
  • Marketing mix for new and legacy products
  • Marketing activities that drive continuing success for legacy brand
  • Best indicators of marketing effectiveness

Participants in this benchmarking research included 28 respondents at 22 leading pharmaceutical, biotech and medical device companies. Product and brand leaders can use this study to review successful strategies and tactics for managing resources and avoiding - or controlling - product cannibalization when marketing multiple brands for the same area of use.

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1066.htm. For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. 


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Maximizing the Potential of Multi-Drug Portfolios Without Cannibalizing from a Legacy Brand
2. PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market
3. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
4. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
8. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
9. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
10. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
11. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation ... day delivery service for patients in the Washington ... traditional retail pharmacy by providing delivery of medications through the ... for future delivery or delivered within one hour to any ... are excited to bring this invaluable service to ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation ... Surgical System to support its strategic sales plan in ... and Virginia.  7D Surgical has entered into an exclusive sales ... medical facilities within those markets. ... Spartan Medical Purchases ...
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... ... their doors. They celebrate 30 years in business this year, and they’re marking ... inviting, tranquil space to serve their patients. , It stands to reason ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... Telehealth, Inc. has received a three-year grant totaling $975,000, renewing its funding from ... Health and Human Services. , This funding marks, the fourth time the HRSA ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA ... endoscope after every reprocessing cycle, both between patient procedures and before storage, is ... Drying is as important to the prevention of disease transmission and nosocomial infection ...
(Date:8/16/2017)... Salt Lake City, Utah (PRWEB) , ... August 16, 2017 , ... ... its spot on the Inc 5000 list for the fourth consecutive year. ... the Inc. 5000 2017 list of the nation’s fastest growing companies. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... First ... United States, named Dr. Douglas J. Harrison, as the new Medical Director of its ... the new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) ...
Breaking Medicine News(10 mins):